Investigating how a specific receptor affects heart disease linked to antipsychotic medications
Role of PXR in drug-elicited cardiovascular disease
This study is looking at how a specific protein in the body might affect heart health for people who take certain antipsychotic medications for a long time, with the goal of finding safer treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Riverside NIH-funded |
| Lab location | 1 site (Riverside, United States) |
| Project ID | NIH-10984990 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the pregnane X receptor (PXR) in the cardiovascular risks associated with long-term use of atypical antipsychotic medications. It aims to uncover the mechanisms by which these medications can lead to dyslipidemia and increased cardiovascular disease risk. By utilizing advanced mouse models, including those with specific genetic modifications, the study will explore how PXR influences lipid metabolism and atherosclerosis. The findings could provide insights into safer treatment options for patients requiring antipsychotic therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with bipolar disorder, schizophrenia, or major depressive disorder who are prescribed atypical antipsychotics.
Not a fit: Patients not taking antipsychotic medications or those with cardiovascular disease unrelated to medication use may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that minimize cardiovascular risks for patients on antipsychotic medications.
How similar studies have performed: Previous research has indicated that understanding the role of PXR in lipid metabolism could lead to significant advancements in managing medication-related cardiovascular risks, suggesting a promising avenue for this investigation.
Where this research is happening
Riverside, United States
- University of California Riverside — Riverside, United States (Active)
Researchers
- Principal investigator: Zhou, Changcheng — University of California Riverside
- Study coordinator: Zhou, Changcheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.